Nature Clinical Practice Oncology | Table 1 : Methylation inhibitor therapy in the treatment of myelodysplastic syndrome

From the following article:

Lewis R Silverman and Ghulam J Mufti

Nature Clinical Practice Oncology (2005) 2, S12-S23
doi:10.1038/ncponc0347

Prognostic variable	Score value
	0	0.5	1.0	1.5	2.0
^aScores are additive (i.e, each is the sum of the scores shown for the three prognostic variables) and their sums are as follows: low, 0; intermediate (INT)-1, 0.5–C1.0; INT-2, 1.5–C2.0; and high, 2.5.
^bGood: normal, -Y, del(5q), or del(20q); poor: complex (3 abnormalities) or chromosome 7 abnormalities; intermediate: other abnormalities.
^cHemoglobin (Hb) <10 g/dl; absolute neutrophil count (ANC) <1,500/ml; platelet count (PLT) <100 $times$ 10⁹/l. —, not applicable. Reproduced with permission from reference 6 © (1997) American Society of Hematology.
Marrow blasts (%)	<5	5–10	—	11–20	21–30
Karyotype^{^b}	Good	Intermediate	Poor	—	—
Cytopenias^{^c}	0 or 1	2 or 3	—	—	—

Downloading may take up to 30 seconds. If the slide opens in your browser, select File > Save As to save it. Download PowerPoint slide (286K)